All statements that address expectations or projections about the future, including without limitation, product development, product launches, regulatory approvals, market position, acquisitions, revenues, expenditures and other financial results, are forward-looking statements.
All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, KV provides the following cautionary statements identifying important economic, political and technology factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.
Such factors include (but are not limited to) the following: (1)
changes in the current and future business environment, including interest
rates and capital and consumer spending; (2) the difficulty of predicting
FDA approvals such as the Gestiva(TM) NDA discussed above, including
timing, and that any period of exclusivity may not be realized; (3)
acceptance and demand for new pharmaceutical products; (4) the introduction
and impact of competitive products and pricing, including as a result of
so-called authorized-generic drugs; (5) new product development and launch,
including the planned launch of Gestiva(TM), including the possibility that
any product launch, including such launch of Gestiva(TM), may be delayed or
that product acceptance may be less than anticipated; (6) reliance on key
strategic alliances; (7) the availability of raw materials and/or products
manufactured for the Company under contract manufacturing arrangements with
third parties; (8) the
|SOURCE KV Pharmaceutical Company|
Copyright©2008 PR Newswire.
All rights reserved